In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Markets for Benign Prostatic Hyperplasia Therapies

This article was originally published in Start Up

Executive Summary

Investor interest in the urology space waxes and wanes; it's attractive because as a niche specialty it has some pretty big patient populations. Benign prostatic hyperplasia (BPH), the benign enlargement of the prostate over time, affects 90% of men by the time they're 80, and half of men at age 60. In Europe, according to European Markets for Benign Prostatic Hyperplasia Drugs, Devices, and Therapies, a report recently published by FDC-Windhover Information's Medtech Insight division, that's 28 million men. But urology goes out of favor from time to time because so many drugs and device therapies that initially looked promising failed to address the majority of BPH sufferers, or worse, caused side effects in a very sensitive part of the body. Now, we seem to be heading into an up-cycle for BPH, in both the device and pharmaceutical segments.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts